NCT05670379 - Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

August 21, 2025

Study Completion Date

August 21, 2025

Conditions

Overweight and ObesityType2diabetes

Interventions

COMBINATION_PRODUCT

Exenatide Implant

Exenatide Implant is a drug:device combination that delivers steady levels of exenatide, a glucagon-like peptide-1(GLP-1) receptor agonist, for an extended period of time following subdermal insertion.

DRUG

Bydureon BCise (exenatide extended release)

glucagon-like peptide-1 (GLP-1) receptor agonist

DRUG

Semaglutide, 1.0 mg/mL

glucagon-like peptide-1 (GLP-1) receptor agonist

Trial Locations (1)

Unknown

CMax, Adelaide